Nuclear actin participates in many essential cellular processes including gene transcription, chromatic remodelling and mRNA processing. Actin shuttles into and out the nucleus through the action of dedicated transport receptors importin-9 and exportin-6, but how this transport is regulated remains unclear. Here we show that RASSF1A is a novel regulator of actin nucleocytoplasmic trafficking and is required for the active maintenance of nuclear actin levels through supporting binding of exportin-6 (XPO6) to RAN GTPase. RASSF1A (Ras association domain family 1 isoform A) is a tumour suppressor gene frequently silenced by promoter hypermethylation in all major solid cancers. Specifically, we demonstrate that endogenous RASSF1A localises to the nuclear envelope (NE) and is required for nucleo-cytoplasmic actin transport and the concomitant regulation of Myocardin-related transcription factor A (MRTF-A), a coactivator of the transcription factor serum response factor (SRF). The RASSF1A/RAN/XPO6/nuclear actin pathway is aberrant in cancer cells where RASSF1A expression is lost and correlates with reduced MTRF/SRF activity leading to cell adhesion defects. Taken together, we have identified a previously unknown mechanism by which the nuclear actin pool is regulated and uncovered a previously unknown link of RASSF1A and MTRF/SRF in tumour suppression.
Introduction
Actin is one of the most highly conserved cytoskeletal proteins and found in all eukaryotic cells. The fundamental roles of actin are critical for biological processes such as determination of cell shape, vesicle trafficking and cell migration-processes often deregulated in transformed cells. While the role of cytoplasmic actin is well established, the presence of nuclear actin is increasingly appreciated to play a crucial role in cellular responses to internal and external mechanical force. Nuclear actin is actively imported and exported through the activity of importin-9 (Dopie et al, 2012) and exportin-6 (Stuven et al, 2003) and has been implicated in transcription (Egly et al, 1984; Hofmann et al, 2004) , cellular differentiation (Sen et al, 2015) and DNA repair (Belin et al, 2015) . Nuclear actin monomers have been shown to directly regulate the Myocardin-related transcription factor A (MRTF-A), a mechanosensitive co-factor of the serum response factor (SRF) transcription pathway (Vartiainen et al, 2007b; Baarlink et al, 2013) .
The Ras-association domain family (RASSF) genes are upstream regulators of the Hippo tumour suppressor pathway. The family is composed of ten members which are divided into two subgroups: i) RASSF 1-6 possess a Ras Association (RA) domain and a SARAH (Sav/Rassf/Hpo) protein-protein interaction domain in the C-terminus, ii) RASSF 7-10 also contain a RA domain at the N-terminus but lack a recognisable SARAH domain (Sherwood et al, 2010) . The RA domains of the RASSF family bind K-RAS, H-RAS, RAP1/2 and RAN GTPases with varying affinity (Avruch et al, 2006; Dallol et al, 2009 ).
The RASSF1A isoform is a bone fide tumour suppressor gene whose inactivation is implicated in the development of a wide range of human tumours including breast, lung and gastrointestinal cancer . Although gene deletion and germline mutations exist, the most widespread loss of RASSF1A function occurs through promoter hypermethylation associated transcriptional silencing . RASSF1A directly binds Hippo kinases, mammalian sterile 20-like kinase 1 and 2 (MST1 and MST2) through the SARAH domain, promoting downstream hippo pathway signaling to YAP1 (Guo et al, 2007; Matallanas et al, 2007) . In response to DNA damage, nuclear RASSF1A is phosphorylated on Ser131 by ATM (ataxia-telangiectasia mutated) or ATR (ATM-and Rad3-Related) kinases, which promotes dimerization and transautophosphorylation of MST2 required for its activation (Pefani et al, 2014; Hamilton et al, 2009) .
Plasma membrane localisation of cytoplasmic RASSF1A occurs in response to growth factor signaling or direct RAS association with the RA domain (Pefani et al, 2016) . However, the localisation of RASSF1A to mitotic structures has been attributed to RA domain binding to tubulin (also a GTP binding protein) and is a likely cause of hyperstabilization of tubulin commonly observed in 3 interphase cells overexpressing exogenous levels (Liu et al, 2003; Dallol et al, 2004; Vos et al, 2004; El-Kalla et al, 2010) .
Here we show that nuclear RASSF1A is recruited to the NE by a lamina-associated pool of the hippo kinase, MST2. Furthermore, we find that RASSF1A is required for the association of exportin-6 (XPO6) with RAN-GTPase, the nuclear export of the XPO6 cargoes, actin and profilin, an actin-binding protein involved in the dynamic sensing of the actin cytoskeleton and the regulation of the MRTF/SRF axis. Tumour cells lacking RASSF1A expression display high levels of nuclear actin/profilin, reduced MRTF levels and low transcription of SRF target genes, including SRF itself. In line with these findings, we find that human tumours display a high level of correlation between RASSF1A and SRF expression, with evidence for low SRF mRNA as a poor prognostic factor in breast and liver cancers.
These events reveal the potential primary mechanism for the tumour suppressor RASSF1A in cancer being mediated through deregulation of nuclear actin transport.
Results

RASSF1A localises at the inner nuclear membrane
RASSF1A acts as a microtubule-associated protein that stabilises microtubules Vos et al, 2004; El-Kalla et al, 2010; Liu et al, 2003) . However, these phenotypes were determined after the accumulation of overexpressed protein over a 24-48 h period. To identify the localisation of endogenous nuclear RASSF1A by indirect immunofluorescence (IF) and methanol fixation, we used an anti-RASSF1A antibody (ATLAS), the specificity of which was validated in cells depleted for RASSF1A (Figs EV1A and B) . Interestingly, in HeLa cells endogenous RASSF1A is distributed predominantly throughout the nuclear interior and at the perinuclear regions. Co-staining of RASSF1A and the inner nuclear membrane (INM) protein Lamin A/C showed a high degree of colocalisation and similar fluorescence intensity profiles ( Fig 1A) . Silencing of RASSF1A resulted in loss of the nuclear ring staining, indicating that the fluorescence signal is specific for RASSF1A ( Fig EV1B) .
Localisation was conserved across multiple cell types including mouse embryonic fibroblasts (MEFs), human retinal pigmented epithelial RPE-1 cells and human embryonic kidney HEK 293 cells ( Fig 1B) .
The RASSF1A gene promoter is highly methylated in the breast carcinoma cell line MDA-MB-231 and therefore significantly downregulated (Montenegro et al, 2012) . Concomitantly, no immunofluorescence was observed in MDA-MB-231 cells, but upon transient transfection with a plasmid expressing RASSF1A, NE localisation of the exogenous protein was evident ( Fig 1C) .
Alternatively, treatment of MDA-MB-231 with the demethylating agent 5'-aza-dC led to the reexpression of endogenous RASSF1A and yielded similar staining ( Fig EV1C) .
We next validated the NE association of RASSF1A, by investigating the co-localisation of RASSF1A with Lamin A/C, using proximity ligation assay (PLA) in HeLa cells. We found that RASSF1A is closely localised to Lamin A/C at the nuclear envelope (NE) ( Fig 1D) , but associates independently as Lamin A/C knockdown did not affect localisation (Fig EV1 B) . These results suggest that Lamin A/C is not necessary for proper targeting of RASSF1A to the NE. To further assess the localisation of RASSF1A in relation to the structure of the NE, HeLa cells were treated with either Triton X-100 or digitonin.
Whereas Triton X-100 is used to permeabilise all cellular membranes, digitonin can permeabilise preferentially the plasma membrane of cultured cells and leave the NE intact. Therefore, only proteins of the outer nuclear membrane (ONM) that face the cytoplasm are detectable in digitoninpermeabilised cells. In Triton X-100-permeabilised HeLa cells RASSF1A co-localises with Lamin A/C ( Fig 1E) . In contrast, neither Lamin A/C nor RASSF1A were detected at the nuclear envelope in digitonin-permeabilised cells. These results support the hypothesis that RASSF1A localises at the inner nuclear membrane (INM) of the NE (Fig 1E) .
The ATM and ATR kinases catalyse phosphorylation of RASSF1A at Ser131 to regulate its activity (Hamilton et al, 2009) . Phosphorylated (Ser131) RASSF1A was present within the nucleus and at the INM of HeLa cells (Fig EV1 D) . To determine whether phosphorylation of RASSF1A on Ser131 by ATM and ATR kinases is required for its localisation at the inner nuclear membrane, HeLa cells were treated with the ATR inhibitor (VE-821) or ATM inhibitor (KU55933). Inhibition of ATR, ATM or combined ATR/ATM activity did not abolish RASSF1A perinuclear localisation ( Fig EV1   E ). Collectively, the above observations show that the RASSF1A association with the NE is specific and not dependent on the kinase activity of ATR and ATM kinases.
RASSF1A localisation at the NE is mediated by MST2
RASSF1A directly binds Mammalian STE20-Like Protein Kinases 1 and 2 (MST1 and MST2) to support maintenance of MST1/2 phosphorylation and activation (Sánchez-Sanz et al, 2016) . Interestingly, mass spectrometry analysis of MST2 eluted fractions from HeLa lysates identified confidently the interaction between MST2 Lamin A/C (Figs 2A, EV2A ) and suggested a potential interaction with Lamin B1. Lamin A/C and B1 both contribute to NE integrity, with Lamin B constituting more stable filaments and Lamin A/C more responsible for stable rigidity. We further examined the cellular localisation of nuclear MST1/2 kinases by IF in HeLa cells (with methanol fixation) and we observed that only MST2, and not MST1, exhibited perinuclear distribution similar to RASSF1A, as shown with co-staining with Lamin B1 (Fig 2B) . To explore the role of MST2 localisation at the NE in relation to RASSF1A, we next reduced MST2 or RASSF1A expression using siRNAs and observed substantial reduction in RASSF1A staining at the INM in the absence of MST2 whereas, RASSF1A knockdown did not affect MST2 NE distribution ( Fig 2C) . Overall these results suggest that MST2 mediates RASSF1A localisation at the INM via lamina association.
RASSF1A binds to XPO6 through its SARAH domain
We previously showed that RASSF1A interacts with RAN GTPase (Dallol et al, 2009 ), a key component in the regulation of nucleocytoplasmic transport. Given our data above showing the localisation of RASSF1A in the INM, we now sought to identify whether RASSF1A plays an active role in the process of RAN-dependent nuclear export. To test our hypothesis, we performed immunoprecipitation using extracts of HeLa cells and antibodies against exportin-1 (CRM1/XPO1), exportin-4 (XPO4), exportin-5 (XPO5), exportin-6 (XPO6) and exportin-7 (XPO7) ( Fig 3A) .
Interestingly, we found that RASSF1A specifically interacts with XPO6, but not with CRM1/XPO1 which is the most conserved and responsible for export of a wide variety of cargoes (Fornerod et al, 1997) .
In order to determine the domain responsible for its interaction with XPO6, we exogenously expressed full-length MYC-RASSF1A and different RASSF1A-truncated mutants in HeLa cells.
Whereas full-length MYC-RASSF1A (aa 1-340) and MYC-RASSF1A (aa 120-340) could specifically precipitate XPO6, no signal was detected with mutants lacking the SARAH domain, MYC-RASSF1A (aa 1-288) and MYC-RASSF1A (aa 120-288) ( Fig 3B) . Overall, these data demonstrate that the SARAH domain of RASSF1A mediates the interaction with XPO6. We further investigated the role of RASSF1A on the association of RAN to XPO6. Most strikingly, RASSF1A seemed to be required for the formation of XPO6/RAN complex, because siRNA-mediated knockdown of RASSF1A concomitantly decreased association between XPO6 and RAN ( Fig 3C) . Notably, XPO6/RAN interaction with RASSF1A does not include MST2, suggesting that this complex may be recruited to the NE via the RASSF1A-MST2 interaction. We next depleted MST2 expression using siRNA and observed decreased complex formation of RASSF1A with both XPO6 and RAN ( Fig 3D) suggesting that failure to interact with MST2 and the NE disrupts XPO6/RAN stability.
RASSF1A is involved in actin and profilin nuclear export process
XPO6 mediates specifically the export of actin and profilin complexes out of the nucleus (Stuven et al, 2003) . We next determined whether RASSF1A plays a role in the XPO6-dependent nuclear export.
Interestingly, subcellular nuclear/cytoplasmic fractionation of HeLa cell lysates clearly demonstrated elevated levels of profilin and actin in the nucleus upon siRNA-mediated silencing of RASSF1A, compared to cells treated with control siRNA, suggesting an impaired nuclear export ( Fig 4A) . Nuclear retention of profilin in HeLa cells treated with siRNA against RASSF1A was further demonstrated by immunofluorescence ( Fig 4B) . Interestingly, RASSF1A gene silencing does not affect the expression levels of XPO6 ( Fig EV3A) . Additionally, to rule out the possibility that nuclear actin accumulation resulted from impaired nuclear import receptor levels, we next examined the protein expression of importin-9 (IPO9), which is required for actin translocation to the nucleus (Dopie et al, 2012) , in the absence of RASSF1A. Western blotting showed no change in the expression of IPO9 upon depletion of RASSF1A, compared to the siCTRL-transfected cells ( Fig   EV3A) . The significance of RASSF1A for XPO6-mediated export process is also evident in MDA-MB-231 cells that lack RASSF1A expression. Strikingly, forcing the expression of RASSF1A either by transiently transfecting MDA-MB-231 cells with a plasmid encoding RASSF1A or by treating cells with the demethylating agent 5'-aza-dC, led to a decrease in actin and profilin nuclear retention ( Fig   4C, 4D) . Taken together, these data strongly indicate that RASSF1A governs the export of actin and profilin out of the nucleus.
Loss of RASSF1A expression alters MRTF-A/SRF axis
Previous studies showed that nuclear actin has been linked to gene transcription (Visa & Percipalle, 2010; Kapoor & Shen, 2014; Grosse & Vartiainen, 2013) , downregulating the expression of MYL9, ITGB1 and PAK1 (Sharili et al, 2016) . Therefore, we measured mRNA levels of these nuclear actinregulated genes and show that these genes were significantly reduced following siRNA-mediated knockdown of RASSF1A in comparison to control (siCTRL) HeLa cells ( Fig 5A) . Furthermore, mRNA encoding the transcription factor OCT4, which is known to be activated by nuclear actin (Yamazaki et al, 2015) , was elevated in HeLa cells depleted of RASSF1A ( Fig 5A) . It is well established that depletion of IPO9 promotes the export of actin from the nucleus (Dopie et al, 2012) . As expected, the expression of actin in nuclear extracts from HeLa cells treated with siRNA against IPO9 was decreased and prevented accumulation even in the absence of export via RASSF1A silencing ( Fig   EV3B) . Moreover, the increased levels of MYL9, ITGB1, PAK1 and OCT4 mRNA upon RASSF1A silencing were rescued in HeLa cells co-depleted of IPO9 ( Fig 5A) .
We next tested whether increased nuclear actin levels arising from RASSF1A depletion have functional consequences for the cells. Since multiple nuclear actin-regulated genes encode for known regulators of cell adhesion (Sharili et al, 2016) , we then assessed whether these cellular functions are affected in RASSF1A-depleted cells. In accordance with our qRT-PCR data, we showed that HeLa cells lacking RASSF1A exhibited a significantly decreased number of adhesive cells ( Fig 5B) .
Accordingly, restoring actin levels in the nucleus by silencing IPO9 in the absence of RASSF1A was sufficient to rescue this effect ( Fig 5B) . Collectively, our data show that RASSF1A has an indirect effect on the expression of genes involved in cell adhesion processes, via regulation of actin levels within the nucleus.
Nuclear actin plays a key role in the regulation of the localisation and activity of Myocardin-related transcription factor A (MRTF-A) , a co-activator of the transcription factor serum response factor (SRF), which regulates the expression of many cytoskeletal genes (Sotiropoulos et al., 1999; Miralles et al., 2003; Vartiainen et al., 2007; Ho et al., 2013) . We next hypothesized that MRTF-A localisation and transcriptional activity of SRF could both be affected by RASSF1A protein levels. Notably, we observed that MRTF-A resides mostly in the cytoplasm in the absence of RASSF1A whereas it is located in both nucleus and cytoplasm in control cells ( Fig 5C) . Increased nuclear actin levels exclude MRTF-A from the nucleus and block SRF-dependent gene transcription (Vartiainen et al, 2007a; Posern et al, 2002) . Accordingly, we showed decreased mRNA levels of the SRF gene together with decreased FBS-stimulated SRF-reporter activity in cells transfected with siRNA against RASSF1A (Figs 5D, EV3C). Silencing IPO9 restored MRTF-A nuclear localisation and SRF expression in RASSF1A-depleted cells (Figs 5C, 5D ). These results demonstrate a correlation between RASSF1A expression and SRF axis regulation, via actin localisation.
We next analysed SRF gene expression from clinical data available from The Cancer Genome Atlas (TCGA) database with the cBioportal tool (http://www.cbioportal.org). RASSF1A methylation is widely appreciated to correlate with adverse prognosis and we find a significant correlation between this epigenetic event and SRF mRNA levels indicating, that loss of nuclear actin regulation and MRTF/SRF is likely to contribute to clinical parameters (Fig 6A, top) . In line with a role in tumour suppression, SRF levels are significantly reduced in invasive breast cancer compared to control normal tissues ; Fig 6B, bottom) . Additionally, Breast Invasive Carcinomas (TCGA) display higher SRF mRNA expression in tumours with high levels of RASSF1A transcript (p<0.0001), which also shows significant linear correlation across the dataset (R=0.28) ( Fig 6B) . We find a matching association of RASSF1A and SRF in Hepato-Cellular Carcinoma (TCGA) (p<0.0001), again with significant linear correlation of RASSF1/SRF transcripts (R=0.29) ( Fig 6C) and further correlations with bladder and colorectal cancer ( Fig EV4) . Notably, SRF mRNA levels were enriched in the RASSF1 high individuals in four distinct cancer types (Figs 6 and EV4). Finally, we examined the Breast and Liver cancer survival statistics in the TCGA and we found that patients with low SRF expression have a poor prognosis for overall survival (Breast HR = 0.8 (0.72 -0.89) Logrank P =5e -5 ; HCC HR = 0.67 (0.47 -0.96) Logrank P =0.027). Overall our data show a correlation of RASSF1 and SRF mRNA expression and SRF levels associate with poor survival.
Discussion
Actin constantly shuttles between the cytoplasm and the nucleus using an active transport mechanism and proper balance of nuclear and cytoplasmic actin pools is necessary to maintain cellular homeostasis (Dingová et al, 2009) . Nuclear actin exported from the nucleus by XPO6, independently of the general export receptor CRM1, and it is imported by IPO9 (Dopie et al, 2012; Stuven et al, 2003) . As for most export processes, XPO6 also requires RAN GTPase to export actin monomers in complex with profilin from the nucleus (Stuven et al, 2003) . We found that lack of RASSF1A, a phenomenon commonly observed in human tumours, leads to accumulation of actin within the nucleus due to defective nuclear export. The direct interaction of RASSF1A with XPO6, a member of the importin-β superfamily of transport receptors, is required for the association with RAN. The XPO6 complex does not appear to include MST2 suggesting that the recruitment of RASSF1A to MST2 at the NE potentially displaces XPO6 binding to the SARAH domain (Dittfeld et al, Reduction in cytoplasmic actin was not evident as a consequence of the defective export, most likely because of the higher actin concentration in the cytoplasm (Fig 4A) . Nuclear actin is a key regulator of transcription and it is required for all three RNA polymerases (Pol I, II and III) (Qi et al, 2011; Philimonenko et al, 2004) . Previous reports showed that expression of nuclear actin negatively regulates multiple genes and results in altered expression of approximately 2000 genes (Yamazaki et al, 2015; Sharili et al, 2016) . Loss of RASSF1A expression alters gene expression and impacts cellular processes, such as cell adhesion. Thus, RASSF1A appears to contribute to the transcriptional activity of the cell and further to its phenotypic changes through its ability to modulate nuclear actin levels. Although nuclear actin levels have not been extensively studied in cancer cells, abnormal subcellular localisation of certain ABPs (actin-binding proteins) is associated with the development carcinogenesis processes (Honda, 2015; Khurana et al, 2011; Savoy & Ghosh, 2013; Loy et al, 2003; Velkova et al, 2010; Patnaik et al, 2016) . A recent study showed that the nuclear actin levels regulated by XPO6 are pivotal for cell proliferation and quiescence and that preventing actin export from the nucleus contributes to malignant progression (Fiore et al, 2017) . Of note, low XPO6 expression and therefore nuclear actin accumulation correlates with poor survival of breast cancer patients (Fiore et al, 2017) .
Mechanotransduction signaling is essential for a broad range of biological functions such as embryogenesis, cell migration, metastasis and epithelial-mesenchymal transition. MRTF-A is a mechanosensitive transcription co-factor which, together with SRF, controls a variety of genes involved in actin cytoskeletal remodelling and growth factor response. MRTF-SRF activation is responsible for immediate transcriptional response to mechanical stimuli (Cui et al, 2015) and perturbed MRTF-SRF signaling axis might partially explain the pathogenesis of certain human diseases (Ho et al, 2013) . We found that the SRF-driven gene transcription activity in response to serum stimulation was severely abrogated in RASSF1A depleted cells ( Fig 4D) . In addition, we also found that RASSF1 expression correlates with SRF expression in a variety of cancers ( Fig 6) . Although there is currently lack of evidence, altered MRTF-SRF signaling may explain the aberrant mechanosensitivity observed often in cancer cells (Tang et al, 2012; Ciasca et al, 2016; Ghosh et al, 2008) .
Epigenetic silencing of the RASSF1A gene has been frequently associated with poor patient outcome across all solid malignancies . Several studies have identified functional roles for RASSF1A mediated tumour suppression that can explain these clinical associations, e.g., hippo pathway regulation (Hamilton et al, 2009; Matallanas et al, 2007) , apoptosis (Vos et al, 2000; Dallol et al, 2004; Vlahov et al, 2015) and DNA damage/repair (Pefani et al, 2014 . However, the widespread prognostic associations imply a perturbation of a biological process that simultaneously contributes to these diverse mechanisms but this remains unexplained. Intriguingly, nuclear actin levels have also been described to contribute to the regulation of hippo pathway (e.g. SRF regulation of YAP) (Foster et al, 2017; Sen et al, 2015) , apoptosis (Sharili et al, 2016) , differentiation (Sen et al, 2015 (Sen et al, , 2017 Xu et al, 2010) and DNA damage/repair (Belin et al, 2015; Yuan & Shen, 2001) . Altogether, our findings indicate that loss of RASSF1A expression results in failure to export nuclear actin, suggesting that both regulatory processes are linked and that the clinical data associated with RASSF1 methylation involves deregulated MRTF/SRF.
Methods
Tissue culture and cell treatments
HeLa, MEFs, HEK293, RPE-1 and MDA-MB-231 cells were cultured in complete DMEM supplemented with 10% foetal bovine serum in 5% CO2 and 20% O2 at 37°C. HeLa cells were purchased from Cancer Research UK, London, or LGC Promochem (ATCC). Inhibitors for ATR kinase activity (VE-821), ataxia telangiectasia mutated (ATM) kinase activity (KU-55933) were used at a concentration of 10 μM. 10 µM 5-aza-2′-deoxycytidine (5'aza-dC; Sigma) was added to the medium, and the cells were incubated for 72 h. Due to its chemical instability, 5'-aza-dC was added to the fresh medium every 24 h. 
Real-time PCR primers
Plasmids
RASSF1A truncation mutants, MYC-RASSF1A 1-288, MYC-RASSF1A 120-340, MYC-RASSF1A120-288 were created by PCR using MYC-tagged RASSF1A as template, as previously shown (Pefani et al, 2016) . MDA-MB-231 cells were transiently transfected with 1 µg of RASSF1A DNA or the empty pcDNA 3.0 plasmid using Lipofectamine 2000 (Invitrogen).
Antibodies
The following antibodies were used in this study: RASSF1A (Atlas, HPA040735), MST1 (Sigma, 
Quantitative real-time PCR analysis
RNA extraction, reverse transcription and qPCR were performed using the Ambion PowerSYBR Green Cells-to-CT kit following manufacturer's instructions in a 7500 FAST Real-Time PCR thermocycler with v2.0.5 software (Applied Biosystems). The mRNA expression level of each gene relative to GAPDH was calculated using the ΔΔCt method. All experiments were performed in triplicates.
Protein extraction and immunoblotting
Cytosolic and nuclear fractions were prepared using the NE-PER Nuclear and Cytosolic Extraction Reagents (Thermo Fisher Scientific) according to the manufacturer's instructions. Sample protein content was determined by the BiCinchoninic Acid Assay protein assay (Thermo Fisher Scientific). Extracts were analyzed by SDS-PAGE using a 10% Bis-Tris Nu-PAGE gels (Invitrogen) and transferred onto PVDF membranes (Millipore).
Subsequent to being washed with PBS containing 1% Tween 20 (PBS-T), the membranes were blocked in 5% bovine serum albumin (BSA) in TBS-T for 1 h at RT, then incubated with the primary antibody overnight at 4°C.
The membranes were incubated with HRP-conjugated secondary antibodies for 1h at room temperature and exposured to X-ray film (Kodak). ImageJ software (NIH) was used for the quantification of th e bands. All bands were normalised against the loading controls.
Immunofluorescence
HeLa cells were grown on coverslips, washed with PBS and fixed with MeOH at 20°C for 20 min. Where indicated, cells were instead fixed in 4% paraformaldehyde and permeabilised either with 0.5% Triton X-100 at room temperature for 5 min or with 40 μg/ml digitonin on ice for 2 min. Coverslips were then incubated with primary antibody for 2 h in PBS with 3% BSA at room temperature. For the 5-Fluorouridine incorporation, cells were incubated with 2 mM 5-FUrd (Sigma) for 20 min, fixed and stained with rat anti-BrdU. Cells were washed with PBS and incubated with secondary anti-rabbit and/or anti-mouse or anti-rat IgG conjugated with Alexa-Flour 488 or Alexa-Flour 568 (Molecular Probes) for 1 h at room temperature. Samples were washed and mounted on coverslips with mounting medium containing DAPI (Invitrogen). Cells were analysed using LSM780 (Carl Zeiss Microscopy) confocal microscope. Fluorescence intensity plots were generated using ImageJ software (NIH).
Duolink PLA
Duolink PLA was performed using the Duolink Red Kit (Sigma). In summary, cells were seeded at a density of 4 × 10 5 cells per well of a 12-well plate. Cells were fixed in 4% formaldehyde after 24 hours, permeabilised and blocked following the manufacturer's instructions. Following incubation with primary antibodies, coverslips were washed and incubated with a mixture of the PLUS/MINUS Duolink ® PLA probes (OlinkBioscience) for 1 hour at 37 °C. Coverslips were then washed and detection of signal was conducted using the Duolink ® detection reagent kit (red) (OlinkBioscience). Coverslips were first incubated with a ligation-ligase mixture for 30 min at 37 °C, washed and further incubated with an amplification-polymerase mixture for 100 min at 37 °C. Subsequently, coverslips were washed and imaged using the Zeiss microscope system. 
Immunoprecipitation
Cell adhesion assay
HeLa cells were transfected with siRNA against RASSF1A or RASSF1A and IPO9 or control and were collected after 48 h. (1×10 5 /ml, 0.5 ml) were re-plated on fibronectin-coated 24-well plate in triplicate. After attachment for the predetermined time (30 min, 60 min and 90 min), the plate was washed to remove the non-adherent cells. The number of adherent cells from 4 random fields of the well was counted microscopically.
SRF reporter assay
Cells were transfected with the SRF luciferase reporter (pGL4.34) using Lipofectamine 2000. pRL Renilla luciferace vector was used as an internal control. Following DNA transfection, cells were rinsed and cultured for 24 hours before treating with FBS. Luciferase assays were carried out in 24-well plates (n=3 wells); cells were treated for 7hours with FBS, then harvested and analyzed using the dual luciferase assay (Promega).
Correlation analysis
The TCGA data were downloaded from the cBioPortal for Cancer Genomics (http://www.cbioportal.org). (Nagy et al, 2018) .
Statistics
For all experiments, statistical analysis was carried out using a Student's t test. All data are expressed as mean ± SEM. 
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Figure legends
Supplementary Figure 2
A. Co-immunoprecipitation of endogenous MST2 with Lamin B and Lamin A/C.
Supplementary Figure 3
A. Western blot analysis of exportin 6 (XPO6) and importin 9 (IPO9) in the absence of RASSF1A.
GAPDH was used as a loading control. 
